Healthcare provider profile · identity verified

Claude-Lyne Valcin, M.D.

Internal Medicine · MIAMI, FL · NPI 1144459876

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	348	98
Trazodone Hcl	Trazodone Hcl	290	73
Eliquis	Apixaban	287	64
Quetiapine Fumarate	Quetiapine Fumarate	258	32
Amlodipine Besylate	Amlodipine Besylate	251	66
Levothyroxine Sodium	Levothyroxine Sodium	247	70
Metoprolol Succinate	Metoprolol Succinate	211	61
Furosemide	Furosemide	193	58
Pantoprazole Sodium	Pantoprazole Sodium	188	77
Mirtazapine	Mirtazapine	186	42
Sertraline Hcl	Sertraline Hcl	164	42
Warfarin Sodium	Warfarin Sodium	164	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	127	35
Gabapentin	Gabapentin	124	38
Lisinopril	Lisinopril	116	35
Simvastatin	Simvastatin	112	24
Metformin Hcl	Metformin Hcl	110	32
Divalproex Sodium	Divalproex Sodium	94	17
Prednisone	Prednisone	84	28
Risperidone	Risperidone	84	15
Myrbetriq	Mirabegron	82	suppressed
Clopidogrel	Clopidogrel Bisulfate	77	18
Memantine Hcl	Memantine Hcl	77	17
Olanzapine	Olanzapine	74	12
Tamsulosin Hcl	Tamsulosin Hcl	73	32
Losartan Potassium	Losartan Potassium	72	33
Bupropion Hcl Sr	Bupropion Hcl	69	12
Carvedilol	Carvedilol	65	23
Duloxetine Hcl	Duloxetine Hcl	62	17
Fluoxetine Hcl	Fluoxetine Hcl	58	17
Donepezil Hcl	Donepezil Hcl	56	20
Spironolactone	Spironolactone	56	19
Januvia	Sitagliptin Phosphate	53	suppressed
Omeprazole	Omeprazole	52	38
Torsemide	Torsemide	52	24
Finasteride	Finasteride	51	16
Escitalopram Oxalate	Escitalopram Oxalate	50	19
Hydralazine Hcl	Hydralazine Hcl	50	13
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	50	suppressed
Jardiance	Empagliflozin	49	11
Carbidopa-Levodopa	Carbidopa/Levodopa	48	suppressed
Trulicity	Dulaglutide	48	suppressed
Metformin Hcl Er	Metformin Hcl	47	12
Potassium Chloride	Potassium Chloride	46	16
Citalopram Hbr	Citalopram Hydrobromide	45	16
Hydrochlorothiazide	Hydrochlorothiazide	44	18
Propranolol Hcl	Propranolol Hcl	44	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	42	41
Pregabalin	Pregabalin	41	suppressed
Xarelto	Rivaroxaban	41	suppressed
Midodrine Hcl	Midodrine Hcl	40	11
Allopurinol	Allopurinol	38	11
Levetiracetam	Levetiracetam	37	suppressed
Novolog Flexpen	Insulin Aspart	37	suppressed
Sucralfate	Sucralfate	37	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	36	20
Doxycycline Hyclate	Doxycycline Hyclate	35	22
Baclofen	Baclofen	34	suppressed
Montelukast Sodium	Montelukast Sodium	34	16
Rosuvastatin Calcium	Rosuvastatin Calcium	33	20
Tramadol Hcl	Tramadol Hcl	33	19
Clonidine Hcl	Clonidine Hcl	32	suppressed
Nyamyc	Nystatin	30	11
Clozapine	Clozapine	29	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	14
Fluticasone Propionate	Fluticasone Propionate	27	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Atenolol	Atenolol	26	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	26	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	25	suppressed
Nystatin	Nystatin	25	14
Topiramate	Topiramate	25	suppressed
Xifaxan	Rifaximin	25	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	suppressed
Humalog Kwikpen U-100	Insulin Lispro	24	suppressed
Famotidine	Famotidine	23	14
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Azithromycin	Azithromycin	22	11
Lorazepam	Lorazepam	22	11
Ssd	Silver Sulfadiazine	22	suppressed
Tradjenta	Linagliptin	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Amantadine	Amantadine Hcl	20	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	16
Albuterol Sulfate Hfa	Albuterol Sulfate	19	15
Buspirone Hcl	Buspirone Hcl	19	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	12
Vitamin D2	Ergocalciferol (Vitamin D2)	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Travoprost	Travoprost	18	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	17	suppressed
Oxycontin	Oxycodone Hcl	17	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	16	suppressed
Diltiazem Hcl	Diltiazem Hcl	16	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	16	suppressed
Gemtesa	Vibegron	16	suppressed
Digoxin	Digoxin	15	11
Diltiazem 12hr Er	Diltiazem Hcl	15	suppressed
Divalproex Sodium Er	Divalproex Sodium	15	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Haloperidol	Haloperidol	15	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	15	suppressed
Ibuprofen	Ibuprofen	15	14
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	15	suppressed
Enulose	Lactulose	14	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Latanoprost	Latanoprost	14	suppressed
Loperamide	Loperamide Hcl	14	11
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Paliperidone Er	Paliperidone	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Calcitriol	Calcitriol	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	13	suppressed
Alendronate Sodium	Alendronate Sodium	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Trimethoprim	Trimethoprim	12	suppressed
Glipizide	Glipizide	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Ivermectin	Ivermectin	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Valproic Acid	Valproic Acid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error